Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.

Pirfenidone Viatris Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresantai - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Abacavir/Lamivudine Viatris [Abacavir/Lamivudine Mylan Pharma] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

abacavir/lamivudine viatris [abacavir/lamivudine mylan pharma]

viatris limited - abakaviras/lamivudinas - plėvele dengtos tabletės - 600 mg/300 mg - lamivudine and abacavir

Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazolas - schizophrenia; bipolar disorder - psicholeptikai - aripiprazolas mylan pharma skiriamas šizofrenijos gydymui suaugusiesiems ir 15 metų ir vyresniems paaugliams. aripiprazole mylan pharma fluorouracilu gydyti vidutinio sunkumo ar sunkius manijos epizodus bipoliniu i sutrikimas ir prevencija, naujos manijos epizodas suaugusiųjų, kurie patyrę vyrauja manijos epizodų ir kurių manijos epizodų atsakė į aripiprazole gydymas. aripiprazole mylan pharma fluorouracilu ir folino iki 12 savaičių, vidutinio sunkumo ir sunkių manijos epizodų bipoliniu i sutrikimas paauglių amžius-nuo 13 metų ir vyresni.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Bisacodyl Viatris [Bisacodyl MEDA] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bisacodyl viatris [bisacodyl meda]

viatris healthcare limited - bisakodilis - dengtos tabletės - 5 mg - bisacodyl

Pemetrexed Viatris [Pemetrexed Mylan] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pemetrexed viatris [pemetrexed mylan]

viatris limited - pemetreksedas - koncentratas infuziniam tirpalui - 25 mg/ml - pemetrexed

Amitriptylinum Viatris [Amitriptylinum MEDA] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

amitriptylinum viatris [amitriptylinum meda]

viatris healthcare limited - amitriptilinas - dengtos tabletės - 25 mg; 10 mg - amitriptyline

Tiotropium bromide Viatris [Tiotropium bromide Mylan] Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

tiotropium bromide viatris [tiotropium bromide mylan]

viatris limited - tiotropis - įkvepiamieji milteliai (kietosios kapsulės) - 18 µg - tiotropium bromide